MCID: PRV006
MIFTS: 57

Pervasive Developmental Disorder

Categories: Mental diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Pervasive Developmental Disorder

MalaCards integrated aliases for Pervasive Developmental Disorder:

Name: Pervasive Developmental Disorder 12 54 15
Pervasive Developmental Disorders 53 32
Pervasive Development Disorder 12 71
Autism Spectrum Disorders 71
Autistic Behavior 71

Classifications:



External Ids:

Disease Ontology 12 DOID:0060040
ICD9CM 34 299.80
ICD10 32 F84 F84.9
UMLS 71 C0154451 C0524528 C0856975 more

Summaries for Pervasive Developmental Disorder

NINDS : 53 The diagnostic category of pervasive developmental disorders (PDD) refers to a group of disorders characterized by delays in the development of socialization and communication skills. Parents may note symptoms as early as infancy, although the typical age of onset is before 3 years of age. Symptoms may include problems with using and understanding language; difficulty relating to people, objects, and events; unusual play with toys and other objects; difficulty with changes in routine or familiar surroundings, and repetitive body movements or behavior patterns. Autism (a developmental brain disorder characterized by impaired social interaction and communication skills, and a limited range of activities and interests) is the most characteristic and best studied PDD. Other types of PDD include Asperger's Syndrome, Childhood Disintegrative Disorder, and Rett's Syndrome. Children with PDD vary widely in abilities, intelligence, and behaviors. Some children do not speak at all, others speak in limited phrases or conversations, and some have relatively normal language development. Repetitive play skills and limited social skills are generally evident. Unusual responses to sensory information, such as loud noises and lights, are also common.

MalaCards based summary : Pervasive Developmental Disorder, also known as pervasive developmental disorders, is related to autism and autism spectrum disorder, and has symptoms including photophobia, restlessness and personality changes. An important gene associated with Pervasive Developmental Disorder is NLGN3 (Neuroligin 3), and among its related pathways/superpathways are Transmission across Chemical Synapses and Neuroscience. The drugs Valproic acid and Acetylcholine have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and eye, and related phenotypes are Decreased viability after Maraba virus infection and Decreased viability after Maraba virus infection

Disease Ontology : 12 A developmental disorder of mental health that refers to a group of five disorders characterized by impairments in socialization and communication, as well as restricted interests and repetitive behaviors.

Wikipedia : 74 The diagnostic category pervasive developmental disorders (PDD), as opposed to specific developmental... more...

Related Diseases for Pervasive Developmental Disorder

Diseases in the Pervasive Developmental Disorder family:

Rare Pervasive Developmental Disorder

Diseases related to Pervasive Developmental Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 187)
# Related Disease Score Top Affiliating Genes
1 autism 35.5 TMLHE TCF20 TBR1 SLC9A9 SHANK2 SCT
2 autism spectrum disorder 35.5 TCF20 TBR1 SHANK2 SCT PTCHD1 NLGN4X
3 asperger syndrome 34.5 SHANK2 NLGN4X NLGN3 MECP2 GABRB3 CNTNAP2
4 childhood disintegrative disease 34.3 SHANK2 NLGN4X NLGN3 MECP2 GABRB3 CNTNAP2
5 landau-kleffner syndrome 33.6 MECP2 KCNQ2 CNTNAP2
6 potocki-lupski syndrome 33.4 TCF20 NLGN4X NLGN3 MECP2
7 specific developmental disorder 33.2 NLGN4X NLGN3 MECP2 FOXP2 CNTNAP2
8 atypical autism 33.2 SHANK2 NLGN4X NLGN3 MECP2 GABRB3
9 attention deficit-hyperactivity disorder 32.7 TCF20 SLC9A9 NLGN4X MECP2 FOXP2 CNTNAP2
10 fragile x syndrome 32.1 SHANK2 NLGN4X NLGN3 MECP2 EIF4E CNTNAP2
11 alacrima, achalasia, and mental retardation syndrome 32.1 TCF20 TBR1 NLGN3 MECP2 KCNQ2
12 tic disorder 32.0 NLGN4X NLGN3 CNTNAP2
13 echolalia 31.7 NLGN4X NLGN3 MECP2 FOXP2 CNTNAP2
14 schizophrenia 31.5 SHANK2 SCT NLGN4X MECP2 GABRB3 FOXP2
15 learning disability 31.5 MECP2 FOXP2 CNTNAP2
16 phelan-mcdermid syndrome 31.4 SHANK2 NLGN4X NLGN3 MECP2 CNTNAP2
17 focal epilepsy 31.3 MECP2 KCNQ2 KCND2 CNTNAP2
18 early myoclonic encephalopathy 31.1 KCNQ2 KCND2 GABRB3
19 rare pervasive developmental disorder 12.7
20 autism 8 11.6
21 autism 6 11.6
22 autism 9 11.6
23 autism x-linked 1 11.4
24 autism x-linked 2 11.4
25 autism x-linked 3 11.4
26 autism x-linked 4 11.4
27 autism x-linked 5 11.4
28 autism x-linked 6 11.4
29 autism 15 11.4
30 autism 16 11.4
31 autism 17 11.4
32 autism 18 11.4
33 autism 3 11.3
34 autism 7 11.3
35 autism 11 11.3
36 autism 12 11.3
37 autism 13 11.3
38 autism 10 11.3
39 rett syndrome 11.2
40 chromosome 16p11.2 deletion syndrome, 220-kb 11.2
41 autism 19 11.2
42 mental retardation, autosomal recessive 41 11.2
43 benign epilepsy with centrotemporal spikes 11.0 MECP2 KCNQ2 GABRB3 FOXP2 CNTNAP2
44 pitt-hopkins-like syndrome 1 11.0 NLGN4X NLGN3 MECP2 CNTNAP2
45 kagami-ogata syndrome 10.9 SHANK2 NLGN4X NLGN3 MECP2
46 epileptic encephalopathy, early infantile, 6 10.9 MECP2 KCNQ2 GABRB3 CNTNAP2
47 west syndrome 10.9 MECP2 KCNQ2 GABRB3 CNTNAP2
48 pitt-hopkins syndrome 10.9 MECP2 CNTNAP2 CHD8
49 early infantile epileptic encephalopathy 10.9 MECP2 KCNQ2 GABRB3 CNTNAP2
50 neonatal period electroclinical syndrome 10.9 MECP2 KCNQ2 GABRB3

Graphical network of the top 20 diseases related to Pervasive Developmental Disorder:



Diseases related to Pervasive Developmental Disorder

Symptoms & Phenotypes for Pervasive Developmental Disorder

UMLS symptoms related to Pervasive Developmental Disorder:


photophobia, restlessness, personality changes, pseudobulbar behavioral symptoms, sleep disturbances

GenomeRNAi Phenotypes related to Pervasive Developmental Disorder according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability after Maraba virus infection GR00252-A-1 9.74 CHD8 FOXP2 GABRB3 PTCHD1 SCT SHANK2
2 Decreased viability after Maraba virus infection GR00252-A-2 9.74 CHD8 FOXP2 GABRB3 PTCHD1 SCT SHANK2
3 Decreased viability after Maraba virus infection GR00252-A-3 9.74 FOXP2

MGI Mouse Phenotypes related to Pervasive Developmental Disorder:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.77 CHD8 CNTNAP2 CTNND2 GABRB3 KCND2 KCNQ2
2 nervous system MP:0003631 9.44 CHD8 CNTNAP2 CTNND2 GABRB3 KCND2 KCNQ2

Drugs & Therapeutics for Pervasive Developmental Disorder

Drugs for Pervasive Developmental Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 243)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Valproic acid Approved, Investigational Phase 4 99-66-1 3121
2
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
3
Lamotrigine Approved, Investigational Phase 4 84057-84-1 3878
4
Lithium carbonate Approved Phase 4 554-13-2
5
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
6
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
7
Buspirone Approved, Investigational Phase 4 36505-84-7 2477
8
Methylphenidate Approved, Investigational Phase 4 113-45-1 4158
9
Guanfacine Approved, Investigational Phase 4 29110-47-2 3519
10
Levomilnacipran Approved, Investigational Phase 4 96847-54-0
11
Milnacipran Approved, Investigational Phase 4 92623-85-3 65833
12
Norepinephrine Approved Phase 4 51-41-2 439260
13
Minocycline Approved, Investigational Phase 4 10118-90-8 5281021
14
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
15
Choline Approved, Nutraceutical Phase 4 62-49-7 305
16
Cysteine Approved, Nutraceutical Phase 4 52-90-4 5862
17
Melatonin Approved, Nutraceutical, Vet_approved Phase 4 73-31-4 896
18 Immunoglobulins Phase 4
19 Antibodies Phase 4
20 Immunoglobulins, Intravenous Phase 4
21 Rho(D) Immune Globulin Phase 4
22 gamma-Globulins Phase 4
23 Vasodilator Agents Phase 4
24 Antidepressive Agents Phase 4
25 Adrenergic Agents Phase 4
26 Anti-Anxiety Agents Phase 4
27 Neurotransmitter Agents Phase 4
28 Pharmaceutical Solutions Phase 4
29 Dopamine Agents Phase 4
30 Dopamine agonists Phase 4
31 Dopamine Antagonists Phase 4
32 Serotonin Receptor Agonists Phase 4
33 Serotonin 5-HT1 Receptor Agonists Phase 4
34 Antipsychotic Agents Phase 4
35 Adrenergic alpha-Agonists Phase 4
36 Antihypertensive Agents Phase 4
37 Adrenergic Agonists Phase 4
38 Serotonin and Noradrenaline Reuptake Inhibitors Phase 4
39 Central Nervous System Stimulants Phase 4
40 Anti-Bacterial Agents Phase 4
41 Antibiotics, Antitubercular Phase 4
42 Atomoxetine Hydrochloride Phase 4
43 Anti-Inflammatory Agents Phase 4
44 Respiratory System Agents Phase 4
45 Anti-Infective Agents Phase 4
46 Antiviral Agents Phase 4
47 Expectorants Phase 4
48 N-monoacetylcystine Phase 4
49 Antioxidants Phase 4
50 Protective Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 442)
# Name Status NCT ID Phase Drugs
1 A Phase IV, Single-site, Open-Label Study to Evaluate the Efficacy of High-Dose Gammaplex in Children on the Autism Spectrum Unknown status NCT02199925 Phase 4 Gammaplex 5%
2 Assessment and Follow Up Study of Children and Adolescent With Bipolar Disorder Unknown status NCT01000402 Phase 4 Psychopharmacotherapy
3 Treatment With Acetyl-Choline Esterase Inhibitors in Children With Autism Unknown status NCT01098383 Phase 4 Acetyl-Choline Esterase Inhibitors and Choline supplements;Indistinguishable placebo tablets, matching both donepezil and choline
4 Guanfacine for the Treatment of Hyperactivity in Pervasive Developmental Disorder Completed NCT01238575 Phase 4 extended-release guanfacine
5 A Study of Memantine Hydrochloride (Namenda®) for Cognitive and Behavioral Impairment in Adults With Autism Spectrum Disorders Completed NCT01333865 Phase 4 Memantine
6 Milnacipran in Autism and the Functional Locus Coeruleus and Noradrenergic Model of Autism Completed NCT01337700 Phase 4 Milnacipran;Placebo
7 The Role of Omega-3 Fatty Acids in the Management of Singaporean Children With Autism Spectrum Disorders Completed NCT01695200 Phase 4
8 Methylphenidate Study in Young Children With Developmental Disorders Completed NCT00517504 Phase 4 Methylphenidate
9 Pilot Study of the Effect of Aripiprazole Treatment in Autism Spectrum Disorders on Functional Magnetic Resonance Imaging (fMRI) Activation Patterns and Symptoms Completed NCT01028820 Phase 4 Aripiprazole
10 Improving Driving in Young People With Autism Spectrum Disorders Completed NCT03538431 Phase 4 Buspirone
11 Open-Label Treatment Trial to Assess the Short-Term Tolerability, Safety, and Efficacy of Methylphenidate Hydrochloride Extended-Release Liquid Formulation in High-Functioning Autism Spectrum Disorder Adults With Attention-Deficit/Hyperactivity Disorder Completed NCT02096952 Phase 4 Methylphenidate extended-release liquid formulation
12 Oxytocin-based Pharmacotherapy for Autism Spectrum Disorders: Investigating the Neural and Behavioral Effects of a Promising Intervention Approach Completed NCT02940574 Phase 4 Syntocinon (Oxytocin)
13 Atomoxetine, Placebo and Parent Management Training in Autism Completed NCT00844753 Phase 4 atomoxetine;Placebo
14 Multisite Study: Acquisition of Social Skills in Children With Autism Using Video Modeling in Parental Training Completed NCT02235467 Phase 4
15 Open Label Trial of Aripiprazole in the Treatment of CD in Adolescents Completed NCT00250705 Phase 4 Aripiprazole
16 A Pilot Study of Cranial Electrotherapy Stimulation[CES] for Generalized Anxiety Disorder Completed NCT00539357 Phase 4
17 The Effect of N-Acetyl Cysteine on Cortical Erosion in Early Stage Schizophrenia Completed NCT01339858 Phase 4 N-Acetyl Cysteine
18 Treatment of Childhood Regressive Autism With Minocycline: an Anti-Inflammatory Agent Active Within the CNS Completed NCT00409747 Phase 4 Minocycline
19 Language-based Learning Skills and ADHD: Impact of Treatment With Sustained-release Guanfacine Completed NCT01146002 Phase 4 Guanfacine (sustained release)
20 An Open-Label Clinical Trial Conducted Via Telepsychiatry of Complementary and Alternative Treatments (Omega-3 Fatty Acids and Inositol vs. N-acetylcysteine) for the Management of Emotional Dysregulation in Youth With Non-verbal Learning Disability (NVLD) and/or Autism Spectrum Disorders (ASD) Recruiting NCT03757585 Phase 4 Open-label Treatment with Omega-3 Fatty Acids + Inositol;Open-label Treatment with N-acetylcysteine
21 Controlled-Release Melatonin (Melatonin CR)for the Treatment of Impaired Sleep Maintenance (ISM) in 4-8 Year Old Children With Autism Spectrum Disorders (ASD). Terminated NCT01033565 Phase 4 Natrol
22 Group Psychoeducational Program for Mothers of Preschool Children With High Functional Pervasive Developmental Disorders: a Randomized Controlled Trial Unknown status NCT01243905 Phase 2, Phase 3
23 Effect of Probiotics on Central Nervous System Functions in Humans Unknown status NCT02793193 Phase 2, Phase 3 Antibiotic
24 Mirtazapine Treatment of Anxiety in Children and Adolescents With Pervasive Developmental Disorders Completed NCT01302964 Phase 3 Placebo;Mirtazapine
25 Pharmacotherapy of Pervasive Developmental Disorders Completed NCT00870727 Phase 3 Aripiprazole oral product;Placebo oral capsule
26 A Randomized, Double-Blind, Placebo-Controlled, Cross-Over Pilot Study of Riluzole for Drug-Refractory Irritability in Autism Spectrum Disorders Completed NCT02081027 Phase 2, Phase 3 Riluzole;placebo
27 A Randomized, Placebo-Controlled Trial of D-Cycloserine for the Enhancement of Social Skills Training in Pervasive Developmental Disorders Completed NCT01086475 Phase 3 D-cycloserine;Placebo
28 Efficacy And Safety Of Risperidone In The Treatment Of Children With Autistic Disorder And Other Pervasive Developmental Disorders: A Canadian, Multicenter, Double-Blind, Placebo-Controlled Study Completed NCT00261508 Phase 3 risperidone
29 Phase III Study of Autism Co-Morbid for Attention Deficit Hyperactivity Disorder Completed NCT00541346 Phase 3 Methylphenidate Transdermal System
30 2/3 Treatment of Anxiety in Autism Spectrum Disorder Completed NCT02028247 Phase 3
31 Phase II/III Clinical Trial of NPC-15 - Verification of the Efficacy for Sleep Disorders of Children With Autism Spectrum Disorders - Completed NCT02757066 Phase 2, Phase 3 NPC-15 Granules Lower Dose;NPC-15 Granules Higher Dose;NPC-15 Placebo Granule
32 To Mirror or Not to Mirror Upon Perceived Eye Contact? The Effect of Oxytocin on Socially Adaptive Mirror System Functioning in Autism Completed NCT03640156 Phase 3 Oxytocin
33 Double Blind Placebo Controlled Trial of Methyl B12 on Behavioral and Metabolic Measures in Children With Autism Completed NCT01039792 Phase 2, Phase 3 Methyl B12
34 Cognitive-Behavioral Treatment for Anxiety Disorders in Children With Autism Spectrum Disorders Completed NCT01178385 Phase 2, Phase 3
35 A Double-blind, Placebo-controlled Study, Followed by an Open-label Extension Study Evaluating the Efficacy and Safety of Risperidone (R064766) in Children and Adolescents With Irritability Associated With Autistic Disorder Completed NCT01624675 Phase 3 Risperidone;Placebo
36 Pharmacogenomics in Autism Treatment Completed NCT00584701 Phase 2, Phase 3 Risperidone
37 Treatment of Overweight Induced by Antipsychotic Medication in Young People With Autism Spectrum Disorders (ASD) Completed NCT01825798 Phase 3 Metformin;Placebo
38 Multisite Controlled Secretin Trial in Autism Completed NCT00065962 Phase 3 secretin, synthetic porcine;secretin, biologically derived porcine
39 Supporting the Well Being of Families of Young Children With Autism Spectrum Completed NCT01021384 Phase 3
40 Galantamine Versus Placebo in Childhood Autism Completed NCT00252603 Phase 3 Galantamine
41 Targeted Pharmacologic Interventions for Autism: A Double-Blind, Placebo-Controlled Trial of Atomoxetine in Children and Adolescents With Autism Completed NCT00498173 Phase 3 Atomoxetine;Placebo
42 ADHD Symptoms in Autism: Cognition, Behavior, Treatment Completed NCT00178503 Phase 2, Phase 3 Methylphenidate-extended release;Methylphenidate-immediate release
43 Testing a Novel Speech Intervention in Minimally Verbal Children With Autism Spectrum Disorder (ASD) Completed NCT03015272 Phase 2, Phase 3
44 A Pilot Study of Oxytocin for the Treatment of Social Impairment in Individuals With High Functioning Autism Spectrum Disorder Active, not recruiting NCT02985749 Phase 3 Intranasal Oxytocin
45 Double-Blind Placebo-Controlled Study of Acamprosate in Autism Active, not recruiting NCT01813318 Phase 2, Phase 3 Acamprosate;Placebo
46 A Multidisciplinary Approach to the Treatment of Encopresis in Children With Autism Spectrum Disorders Suspended NCT03197922 Phase 3
47 An Open-Label Extension Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of STX209 (Arbaclofen) in Subjects With Autism Spectrum Disorders Terminated NCT01706523 Phase 3 STX209 (arbaclofen)
48 Oxytocin in Adolescents With Autism Spectrum Disorders Terminated NCT02007447 Phase 2, Phase 3 OCYTOCINA - SPRAY NASAL
49 Randomized, Placebo Controlled Double-blind Study of the Efficacy of Topiramate on the Symptoms of Irritability - Impulsivity, Overeating and Self-harm in a Population of Patients Suffering From Prader Willi Syndrome Over 8 Weeks Terminated NCT02810483 Phase 3 Topiramate;Placebo Comparator
50 Initial Development of Cortical Metrics, an Objective, Physiologically-Based Outcome Measure, for Intervention Trials in Autism Spectrum Disorders (ASD) Withdrawn NCT02212275 Phase 2, Phase 3 Dextromethophan

Search NIH Clinical Center for Pervasive Developmental Disorder

Genetic Tests for Pervasive Developmental Disorder

Anatomical Context for Pervasive Developmental Disorder

MalaCards organs/tissues related to Pervasive Developmental Disorder:

40
Brain, Testes, Eye, Liver, Bone, Bone Marrow, Cortex

Publications for Pervasive Developmental Disorder

Articles related to Pervasive Developmental Disorder:

(show top 50) (show all 1941)
# Title Authors PMID Year
1
Methyl-CpG-binding protein 2 (MECP2) gene mutations in an Italian sample of patients with pervasive developmental disorder and mental retardation. 61 54
19189931 2009
2
[Autism, epilepsy and genetics]. 54 61
18302128 2008
3
Serotonin transporter intron 2 polymorphism associated with rigid-compulsive behaviors in Dutch individuals with pervasive developmental disorder. 54 61
15635668 2005
4
Secretin is an ineffective treatment for pervasive developmental disabilities: a review of 15 double-blind randomized controlled trials. 61 54
15590241 2005
5
X-linked mental retardation and autism are associated with a mutation in the NLGN4 gene, a member of the neuroligin family. 61 54
14963808 2004
6
Multiple pathways regulate MeCP2 expression in normal brain development and exhibit defects in autism-spectrum disorders. 61 54
14734626 2004
7
Absence of MeCP2 mutations in patients from the South Carolina autism project. 61 54
12555243 2003
8
Minor form of trigonocephaly is an autistic skull shape? A suggestion based on homeobox gene variants and MECP2 mutations. 54 61
12027529 2002
9
Pervasive developmental disorders and GABAergic system in patients with inverted duplicated chromosome 15. 61 54
11785506 2001
10
How has DSM-5 Affected Autism Diagnosis? A 5-Year Follow-Up Systematic Literature Review and Meta-analysis. 61
30852784 2020
11
Temporal trends in incidence of Rolandic epilepsy, prevalence of comorbidities and prescribing trends: birth cohort study. 61
31937568 2020
12
Risk of early neurodevelopmental outcomes associated with prenatal exposure to the antiepileptic drugs most commonly used during pregnancy: a French nationwide population-based cohort study. 61
32513880 2020
13
A Phase II Randomized Clinical Trial of the Safety and Efficacy of Intravenous Umbilical Cord Blood Infusion for Treatment of Children with Autism Spectrum Disorder. 61
32444220 2020
14
A new machine learning model based on induction of rules for autism detection. 61
30693818 2020
15
Adult Manifestation of Milder Forms of Autism Spectrum Disorder; Autistic and Non-autistic Psychopathology. 61
32052317 2020
16
The yield of structural magnetic resonance imaging in autism spectrum disorders. 61
30546152 2019
17
Psychiatric and neurodevelopmental aspects of Becker muscular dystrophy. 61
31708335 2019
18
A comparative study of the genetic components of three subcategories of autism spectrum disorder. 61
29875476 2019
19
Sleep problems in children who stutter: Evidence from population data. 61
31522013 2019
20
Diagnostic trajectories in child and adolescent mental health services: exploring the prevalence and patterns of diagnostic adjustments in an electronic mental health case register. 61
31679098 2019
21
Isolated oligohydramnios and long-term neurological morbidity of the offspring. 61
31755400 2019
22
Knockout of latrophilin-3 in Sprague-Dawley rats causes hyperactivity, hyper-reactivity, under-response to amphetamine, and disrupted dopamine markers. 61
31176715 2019
23
Autism spectrum disorder in children with Type 1 diabetes. 61
31271682 2019
24
Effect of Fluoxetine on Obsessive-Compulsive Behaviors in Children and Adolescents With Autism Spectrum Disorders: A Randomized Clinical Trial. 61
31638682 2019
25
The relationship between symptoms of autism spectrum disorder and visual impairment among adults with intellectual disability. 61
31136093 2019
26
Down syndrome as a genetic model to evaluate the role of oxidative stress and transsulfuration abnormalities in autism spectrum disorder: A 10-year longitudinal cohort study. 61
31742925 2019
27
Aripiprazole for treating irritability associated with autism spectrum disorders. 61
31180743 2019
28
Need For Long-Term Care in Children is Increasingly Caused by Disorders of Psychological Development. Changes in the Care Causing Diagnoses According to German Social Code (SGB XI) Between 2009-2014. 61
29788530 2019
29
Predictive components in the structure of an intensive, parent mediated, early intervention for children with autism spectrum disorders in India. 61
31463233 2019
30
DSM-5 criteria for autism spectrum disorder maximizes diagnostic sensitivity and specificity in preschool children. 61
30850887 2019
31
Management of Self-injurious Behaviors in Children with Neurodevelopmental Disorders: A Pharmacotherapy Overview. 61
30793794 2019
32
Feasibility and Outcomes of the Early Start Denver Model Implemented with Low Intensity in a Community Setting in Austria. 61
31107360 2019
33
Frequency and association of mitochondrial genetic variants with neurological disorders. 61
30218715 2019
34
Diagnostic validity of the MINI-KID disorder classifications in specialized child and adolescent psychiatric outpatient clinics in Sweden. 61
31072319 2019
35
Neuromodulation of autism spectrum disorders using vagal nerve stimulation. 61
30732986 2019
36
Prevalence and Characteristics of Autism Spectrum Disorder Among Children Aged 4 Years - Early Autism and Developmental Disabilities Monitoring Network, Seven Sites, United States, 2010, 2012, and 2014. 61
30973853 2019
37
Relationship in Quality of Diet, Food Habit and Feeding Practice in Children with Pervasive Developmental Disorder and Their Caregiver. 61
31089463 2019
38
Psychiatric comorbidity in persons with high-functioning autism spectrum disorders: Findings from a tertiary care neuropsychiatric hospital. 61
30316630 2019
39
Impaired innate and conditioned social behavior in adult C57Bl6/J mice prenatally exposed to chlorpyrifos. 61
30823929 2019
40
Child and Adolescent Psychosocial Care Center service use profile in Brazil: 2008 to 2012. 61
30540024 2019
41
Five-year diagnostic stability among adolescents in an inpatient psychiatric unit. 61
30583125 2019
42
Patterns of Nonsocial and Social Cognitive Functioning in Adults With Autism Spectrum Disorder: A Systematic Review and Meta-analysis. 61
30601878 2019
43
A 17-Year-Old Boy With High-Functioning Autism, Gastrointestinal Illness, and Seizures. 61
30545828 2019
44
Autism and social anxiety in children with sex chromosome trisomies: an observational study. 61
31231689 2019
45
Dietary Patterns Impact Temporal Dynamics of Fecal Microbiota Composition in Children With Autism Spectrum Disorder. 61
31998741 2019
46
Characterization of an Animal Model of Autism and Social Interaction. 61
30535692 2019
47
Everolimus for epilepsy and autism spectrum disorder in tuberous sclerosis complex: EXIST-3 substudy in Japan. 61
30060984 2019
48
Role of Vitamin D in Autism Spectrum Disorder. 61
31755381 2019
49
Disruptive Behaviors across Different Disorders: Evaluation of a Clinical Sample Using the Eyberg Child Behavior Inventory. 61
30022702 2019
50
Acceptability of the Transitional Wearable Companion "+me" in Typical Children: A Pilot Study. 61
30800083 2019

Variations for Pervasive Developmental Disorder

ClinVar genetic disease variations for Pervasive Developmental Disorder:

6 (show top 50) (show all 74) ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 NLGN3 NM_181303.2(NLGN3):c.1600C>T (p.Pro534Ser)SNV Pathogenic 631481 rs1569485503 X:70387547-70387547 X:71167697-71167697
2 NCKAP1 NM_013436.5(NCKAP1):c.3240_3241del (p.Asn1080fs)deletion Pathogenic 834055 2:183791573-183791574 2:182926845-182926846
3 ASF1A , CEP85L , DCBLD1 , FAM184A , GOPC , MCM9 , NUS1 , PLN , SLC35F1 NC_000006.11:g.(117810940_117810996)_(119417693_119417749)deldeletion Pathogenic 180223 6:117810940-119417749
4 PPP2R1A NM_014225.6(PPP2R1A):c.773G>A (p.Arg258His)SNV Pathogenic 217458 rs863225094 19:52716329-52716329 19:52213076-52213076
5 46;XY;inv(3)(p13q21)dninversion Pathogenic 267814
6 46;XY;t(7;19)(q32;q13.1)dnTranslocation Pathogenic 267828
7 46;XY;t(6;12)(q14;q24);20p+dncomplex Pathogenic 267833
8 46;XY;t(2;22)(q23;q13)dnTranslocation Pathogenic 267838
9 46;XY;t(9;11)(q34;p11.2)dnTranslocation Pathogenic 267847
10 46;XY;t(8;10)(q13;p13)dnTranslocation Pathogenic 267850
11 46;XY;t(2;6)(q33;q21)dnTranslocation Pathogenic 267885
12 46;XY;t(5;15)(q11.2;q24)Translocation Pathogenic 267937
13 46;XY;inv(12)(p12.1q21.2)dninversion Pathogenic 267954
14 46;XX;t(3;14)(q25;q11.2)dnTranslocation Pathogenic 267955
15 46;XX;inv(7)(q11.23q36.3)dninversion Pathogenic 267882
16 46;XX;t(19;21)(q13.3;q22.3)dnTranslocation Pathogenic 268035
17 46;XY;t(3;18)(q13.31;q22.1)dnTranslocation Pathogenic 268039
18 TBR1 NM_006593.4(TBR1):c.1581_1587GGCTGCA[3] (p.Thr532fs)short repeat Pathogenic/Likely pathogenic 224144 rs869312704 2:162280263-162280264 2:161423752-161423753
19 KCNQ2 NM_172107.4(KCNQ2):c.1004C>T (p.Pro335Leu)SNV Pathogenic/Likely pathogenic 205892 rs796052641 20:62069997-62069997 20:63438644-63438644
20 TCF20 NM_005650.3(TCF20):c.5725C>T (p.His1909Tyr)SNV Pathogenic/Likely pathogenic 590780 rs1569110700 22:42575639-42575639 22:42179633-42179633
21 GRIN1 NM_007327.4(GRIN1):c.2531G>T (p.Arg844Leu)SNV Likely pathogenic 598966 rs1564365418 9:140058298-140058298 9:137163846-137163846
22 GRIN2B NM_000834.4(GRIN2B):c.2225G>T (p.Arg742Ile)SNV Likely pathogenic 523382 rs1555103646 12:13722898-13722898 12:13569964-13569964
23 ZBTB20 NM_001348803.2(ZBTB20):c.1955A>T (p.His652Leu)SNV Likely pathogenic 585297 rs1560092224 3:114058123-114058123 3:114339276-114339276
24 TBR1 NM_006593.4(TBR1):c.471del (p.Ala156_Tyr157insTer)deletion Likely pathogenic 523672 rs1553510171 2:162273392-162273392 2:161416881-161416881
25 TBR1 NM_006593.4(TBR1):c.673A>T (p.Ile225Phe)SNV Likely pathogenic 523673 rs1553510217 2:162273594-162273594 2:161417083-161417083
26 TBR1 NM_006593.4(TBR1):c.713_719del (p.Ser238fs)deletion Likely pathogenic 523674 rs1553510280 2:162274201-162274207 2:161417690-161417696
27 TBR1 NM_006593.4(TBR1):c.811T>C (p.Trp271Arg)SNV Likely pathogenic 523675 rs1553510301 2:162274305-162274305 2:161417794-161417794
28 TBR1 NM_006593.4(TBR1):c.844C>T (p.Gln282Ter)SNV Likely pathogenic 523677 rs1553510313 2:162274338-162274338 2:161417827-161417827
29 TBR1 NM_006593.4(TBR1):c.896G>A (p.Trp299Ter)SNV Likely pathogenic 523678 rs1553510385 2:162274760-162274760 2:161418249-161418249
30 TBR1 NM_006593.4(TBR1):c.1155C>G (p.Asn385Lys)SNV Likely pathogenic 523680 rs762713626 2:162276733-162276733 2:161420222-161420222
31 TBR1 NM_006593.4(TBR1):c.1177dup (p.Asp393fs)duplication Likely pathogenic 523681 rs1553510680 2:162276752-162276753 2:161420241-161420242
32 TBR1 NM_006593.4(TBR1):c.1369_1371delinsCA (p.Thr457fs)indel Likely pathogenic 523682 rs1553511175 2:162280058-162280060 2:161423547-161423549
33 TBR1 NM_006593.4(TBR1):c.1639_1648dup (p.Pro550fs)duplication Likely pathogenic 523683 rs1553511216 2:162280326-162280327 2:161423815-161423816
34 TBR1 NM_006593.4(TBR1):c.1653_1654del (p.Gln552fs)deletion Likely pathogenic 523685 rs1553511226 2:162280341-162280342 2:161423830-161423831
35 subset of 21 genes: SLC4A10 , TBR1 deletion Likely pathogenic 523686 2:160075929-164666149
36 TBR1 deletion Likely pathogenic 523687 2:161561653-163178787
37 TBR1 deletion Likely pathogenic 523688 2:161967492-162428730
38 CNTN6 NM_001289080.2(CNTN6):c.566C>A (p.Ser189Ter)SNV Likely pathogenic 548950 rs773080572 3:1337396-1337396 3:1295712-1295712
39 RSRC2 NM_023012.6(RSRC2):c.425G>A (p.Arg142Gln)SNV Likely pathogenic 242899 rs752134549 12:123001951-123001951 12:122517404-122517404
40 46;XX;t(6;13)(q21;q32)dnTranslocation Likely pathogenic 267869
41 46;XY;t(1;2)(q31.2;p15)Translocation Likely pathogenic 267880
42 46;XX;inv(5)(p12q13.1)dninversion Likely pathogenic 267886
43 46;XY;t(1;4)(q21.3;p15.2)dnTranslocation Likely pathogenic 267901
44 46;XY;t(1;12)(p32;p13)dnTranslocation Likely pathogenic 267906
45 FMR1 NM_002024.5(FMR1):c.199-2A>GSNV Likely pathogenic 374035 rs1057518850 X:147009838-147009838 X:147928320-147928320
46 46;XY;t(3;5)(q23;q13)dnTranslocation Likely pathogenic 267884
47 46;XX;t(6;21)(q14;q21)dnTranslocation Likely pathogenic 268025
48 CACNA1A NM_000068.4(CACNA1A):c.*478_*483deldeletion Conflicting interpretations of pathogenicity 598990 rs1568415991 19:13318377-13318382 19:13207563-13207568
49 WFS1 NM_006005.3(WFS1):c.2603G>A (p.Arg868His)SNV Conflicting interpretations of pathogenicity 215403 rs56393026 4:6304125-6304125 4:6302398-6302398
50 MEFV NM_000243.2(MEFV):c.2080A>G (p.Met694Val)SNV Conflicting interpretations of pathogenicity 2538 rs61752717 16:3293407-3293407 16:3243407-3243407

Expression for Pervasive Developmental Disorder

Search GEO for disease gene expression data for Pervasive Developmental Disorder.

Pathways for Pervasive Developmental Disorder

Pathways related to Pervasive Developmental Disorder according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.29 SHANK2 NLGN4X NLGN3 KCNQ2 KCND2 GABRB3
2 11.63 TBR1 SHANK2 MECP2 KCNQ2 KCND2 CNTNAP2
3
Show member pathways
11.45 SHANK2 NLGN4X NLGN3

GO Terms for Pervasive Developmental Disorder

Cellular components related to Pervasive Developmental Disorder according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 10.23 SLC9A9 SHANK2 PTCHD1 PPP2R1A NLGN4X NLGN3
2 cell projection GO:0042995 9.95 SHANK2 PPP2R1A NCKAP1 KCND2 CTNND2 CNTNAP2
3 cell junction GO:0030054 9.7 SHANK2 NLGN4X NLGN3 KCND2 GABRB3 CTNND2
4 postsynapse GO:0098794 9.67 NLGN3 MECP2 EIF4E
5 postsynaptic membrane GO:0045211 9.67 SHANK2 NLGN4X KCND2 GABRB3
6 voltage-gated potassium channel complex GO:0008076 9.61 KCNQ2 KCND2 CNTNAP2
7 dendrite GO:0030425 9.43 SHANK2 PPP2R1A NLGN4X KCND2 CTNND2 CNTNAP2
8 spanning component of membrane GO:0089717 9.4 NLGN4X NLGN3
9 asymmetric, glutamatergic, excitatory synapse GO:0098985 9.32 NLGN4X NLGN3
10 synapse GO:0045202 9.28 SHANK2 PTCHD1 PPP2R1A NLGN4X NLGN3 MECP2
11 symmetric, GABA-ergic, inhibitory synapse GO:0098983 9.26 NLGN4X NLGN3

Biological processes related to Pervasive Developmental Disorder according to GeneCards Suite gene sharing:

(show all 23)
# Name GO ID Score Top Affiliating Genes
1 brain development GO:0007420 9.77 TBR1 SCT MECP2 CNTNAP2 CHD8
2 cerebral cortex development GO:0021987 9.7 TBR1 FOXP2 CNTNAP2
3 chemical synaptic transmission GO:0007268 9.7 PTCHD1 NLGN4X NLGN3 MECP2 KCNQ2 KCND2
4 synapse assembly GO:0007416 9.67 SHANK2 NLGN3 MECP2
5 learning GO:0007612 9.65 SHANK2 NLGN4X NLGN3 MECP2 CNTNAP2
6 synapse organization GO:0050808 9.63 NLGN4X NLGN3 CTNND2
7 adult behavior GO:0030534 9.62 SHANK2 NLGN4X NLGN3 CNTNAP2
8 regulation of AMPA receptor activity GO:2000311 9.61 SHANK2 NLGN3
9 dendritic spine morphogenesis GO:0060997 9.61 SHANK2 CTNND2
10 cerebellum development GO:0021549 9.61 NLGN4X MECP2 FOXP2
11 startle response GO:0001964 9.6 MECP2 CHD8
12 neuron cell-cell adhesion GO:0007158 9.59 NLGN4X NLGN3
13 presynapse assembly GO:0099054 9.58 NLGN4X NLGN3
14 thalamus development GO:0021794 9.58 PTCHD1 CNTNAP2
15 long-term synaptic potentiation GO:0060291 9.58 SHANK2 NLGN3 MECP2
16 regulation of respiratory gaseous exchange by neurological system process GO:0002087 9.57 NLGN3 MECP2
17 presynaptic membrane assembly GO:0097105 9.56 NLGN4X NLGN3
18 negative regulation of excitatory postsynaptic potential GO:0090394 9.55 NLGN4X NLGN3
19 inhibitory postsynaptic potential GO:0060080 9.54 NLGN3 GABRB3
20 postsynaptic membrane assembly GO:0097104 9.51 NLGN4X NLGN3
21 vocal learning GO:0042297 9.48 FOXP2 CNTNAP2
22 vocalization behavior GO:0071625 9.26 SHANK2 NLGN4X NLGN3 CNTNAP2
23 social behavior GO:0035176 9.17 SHANK2 PTCHD1 NLGN4X NLGN3 MECP2 CNTNAP2

Molecular functions related to Pervasive Developmental Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 neurexin family protein binding GO:0042043 8.62 NLGN4X NLGN3

Sources for Pervasive Developmental Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....